接受玻璃体腔抗VEGF注射的黄斑变性患者脑健康评估(BHAM研究):中期分析
注射超过20次组较对照组轻度认知障碍可能性更高,平均Z评分更差且差异有统计学意义(P=0.04)。研究未设计因果推断,但提示需进一步研究。
要点
- 累计抗VEGF注射超过20次者轻度认知障碍风险高于未注射对照组。
- 两组平均Z评分差异有统计学意义(P=0.04)。
- 研究为中期分析,不能证明抗VEGF注射与认知下降的因果关系。
核心结论
- 累计抗VEGF注射次数越多与认知健康变差相关,但研究未设计因果推断,仅提示需进一步研究。
研究设计与样本
- 患者接受iPad式脑健康评估以判定轻度认知障碍风险,并与每人累计抗VEGF注射次数比较。
- 按注射次数分为0次对照组、1至9次、10至20次和超过20次四组。
主要发现
- 注射超过20次组较对照组轻度认知障碍可能性更高,平均Z评分更差且差异有统计学意义(P=0.04)。
关键数值与推荐
- 注射超过20次组与对照组平均Z评分差异P=0.04。
临床怎么用
- 对需长期多次玻璃体腔抗VEGF注射的患者,可关注其认知功能状态并在随访中留意变化。
- 该关联尚不能改变临床注射决策,需结合个体获益与风险综合评估。
局限性
- 研究为中期分析,未设计用于证明因果关系。
- 原文未报告样本量之外的组间具体Z评分数值及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: After intravitreal injection, anti-vascular endothelial growth factor (VEGF) agents are found in the systemic circulation and can suppress systemic VEGF levels. Neuronal health and cognitive function in the central nervous system have been associated with normal physiological levels of VEGF expression. We wished to determine whether there was an association between cumulative anti-VEGF exposure and cognitive function. METHODS: One hundred and seventy-five patients aged 65 to 85 with vision of at least 20/50 or better in one eye and a diagnosis of age-related macular degeneration took an iPad-based brain health assessment to determine their risk of mild cognitive impairment. The result for each patient was compared with the total number of anti-VEGF injections per individual patient. Patients were then stratified into groups with 0 injections (control), 1 to 9 injections, 10 to 20 injections, or greater than 20 injections. RESULTS: The group of patients with more than 20 injections had a higher likelihood of mild cognitive impairment compared with the control group, with statistically significant worse mean Z-scores (P = 0.04). CONCLUSION: Our study is the first to associate worsening cognitive health with higher cumulative anti-VEGF injections. This study was not designed to show a causal link, but does suggest that additional investigation is warranted.
引用
- Ray SK, Manz SN. BRAIN HEALTH ASSESSMENT IN MACULAR DEGENERATION PATIENTS UNDERGOING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS (THE BHAM STUDY): An Interim Analysis. Retina. 2021. PMID: 33346625. doi:10.1097/IAE.0000000000003066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。